Nyxoah מגייסת 27 מיליון דולר באמצעות הנפקת השוק שלה
השקעה של משקיע חדש מתחום הבריאות בארצות הברית מחזקת את המאזן ואת ההתמקדות בארצות הברית
מונט-סנט-גיברט, בלגיה, 7 באוקטובר 2024, (GLOBE NEWSWIRE) :
Nyxoah SA (נאסד"ק/יורונקסט בריסל: NYXH) חברת טכנולוגיה רפואית המפתחת חלופות טיפול פורצות דרך לדום נשימה חסימתי בשינה (OSA) באמצעות אפנון עצבי, הודיעה היום כי החברה מכרה 3.0 מיליון מניות שהכניסו לחברה 27.0 מיליון דולר ברוטו, בהתאם להנפקת השוק הכוללת של החברה בגובה של 50 מיליון דולר, במחיר למניה השווה למחיר השוק בשוק העולמי של נאסד"ק בעת המכירה. המניות נמכרו, על סמך ריבית שהתקבלה, למשקיע יחיד בארצות הברית מתחום הרפואה. Cantor Fitzgerald & Co משמשים כסוכני המכירות של ההנפקה.
INSIDE INFORMATION
REGULATED INFORMATION
Nyxoah Raises $27 Million through its At-the-Market Offering
Investment by a new U.S.-based healthcare investor, strengthening the balance sheet and reinforcing U.S. focus
Mont-Saint-Guibert, Belgium – October 7, 2024, 11:00pm CET / 5:00pm ET, (GLOBE NEWSWIRE):
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company has sold 3.0 million shares raising $27.0 million in gross proceeds pursuant to the Company’s $50 million at-the-market ("ATM") offering at a price per share equal to the market price on the Nasdaq Global Market at the time of sale. The shares were sold, based on interest received, to a single U.S.-based healthcare investor. Cantor Fitzgerald & Co. is acting as the sales agent for the ATM offering.
The ordinary shares described above were sold by the Company pursuant to the Company’s shelf registration statement on Form F-3 (File No. 333-268955), filed with the Securities and Exchange Commission ("SEC") on December 22, 2022, which became effective on January 6, 2023, and which included a prospectus supplement and accompanying prospectus related to the ATM offering. Copies of the prospectus supplement and accompanying prospectus related to the ATM offering may be obtained from Cantor Fitzgerald & Co., attention: Capital Markets, 110 East 59th Street, 6th Floor, New York, New York 10022; email: [email protected]. Electronic copies of the prospectus are also available on the SEC's website at http://www.sec.gov.
Olivier Taelman, Chief Executive Officer of Nyxoah, commented: "After relocating to the United States with my family this past summer, this investment reinforces our United States focus, builds on our compelling DREAM pivotal study data presented at the International Surgical Sleep Society (ISSS) congress and strengthens our financial position, providing additional opportunities as we are preparing for the launch of Genio® in the United States."
About Nyxoah
Nyxoah is reinventing sleep for the billion people that suffer from obstructive sleep apnea (OSA). We are a medical technology company that develops breakthrough treatment alternatives for OSA through neuromodulation. Our first innovation is Genio®, a battery-free hypoglossal neuromodulation device that is inserted through a single incision under the chin and controlled by a wearable. Through our commitment to innovation and clinical evidence, we have shown best-in-class outcomes for reducing OSA burden.
Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study for FDA and U.S. commercialization approval.
Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.
Contacts:
Nyxoah
Loïc Moreau, Chief Financial Officer
[email protected]
For Media
In United States
FINN Partners – Glenn Silver
[email protected]
In Belgium/France
Backstage Communication – Gunther De Backer
[email protected]
In International/Germany
MC Services – Anne Hennecke
[email protected]
Attachment
- ENGLISH_ATM Transaction Release
*** הידיעה מופצת בעולם על ידי חברת התקשורת הבינלאומית GlobeNewswire